Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2022-01-24 Major Shareholding Noti…
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
COWEN FINANCIAL PRODUCTS LLC
Major Shareholding Notification
2022-01-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a license and collaboration agreement), preliminary financial information to be presented at a conference, and a press release. It does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It also includes a presentation and press release as exhibits, but the main document is a regulatory announcement of these events. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-01-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 14, 2021. The content describes the approval and adoption of a new Code of Conduct by the Board of Directors, replacing the previous Code. This is an announcement related to governance practices, specifically amendments to the company's Code of Ethics. There is no financial data, earnings information, or detailed report content. The document is not a full annual or quarterly report, nor is it a proxy statement or voting result. It is a regulatory filing announcing a governance change. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 3405 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2021-12-17 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes clinical trial results and a press release announcement related to the company's Phase 1/2a MONARCH Study findings. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, governance, or management change filing. It is an announcement of other events, specifically clinical trial results and a press release. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-12-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.